Zydus unveils Bemdac to treat bad cholesterol in India
Bempedoic acid has also shown to have good results in patients not able to tolerate statins and those who do not respond to statins.;
Ahmedabad: Global lifesciences company, Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced the launch of Bemdac (Bempedoic acid), a new class of drug for the first time in India.
The oral drug ushers in a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite life-style modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management. LDL-c is often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, increasing the chances of health problems like heart attack or stroke. Uncontrolled LDL-c is a major risk factor for developing cardiovascular diseases.
According to studies, 8 out of 10 Indians are dyslipidemic and 112 million adults suffer from high levels of LDL-c. 7 out of 10 dyslipidemia patients who are on statin treatment continue to suffer from uncontrolled LDL-c. Besides this, 5.4 million Indians are found to be intolerant to statin therapy.
Bempedoic acid has also shown to have good results in patients not able to tolerate statins and those who do not respond to statins. This is a huge unmet healthcare need which Bemdac addresses.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.